FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
06/05/2024
/
Publications
/
FLASH Therapy
Dosimetry
Toxicity
A review article by the Upenn group summarized the preclinical and clinical evidence for the FLASH effect and discussed the potential clinical significance for...
Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma
14/05/2021
/
Publications
/
Dosimetry
This study included148 chordoma and chondrosarcoma patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1cm3...
Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy.
14/09/2021
/
Publications
/
Toxicity
This study reported outcomes of 48 patients with skull base chondrosarcoma who underwent particle therapy (67% PT, 33% CIRT). With a median follow-up of 38...
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas.
14/06/2022
/
Publications
/
Survival
Dosimetry
Sixty-seven patients with unresected spinal chordomas treated with PBT were evaluated. With a median follow-up of 56.2 months, 5- and 8-year OS were 83.5 % and...
Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience.
14/03/2023
/
Publications
/
Toxicity
This study reported clinical outcomes of 44 patients treated with proton (89%) or carbon ion therapy (11%). At a median follow-up of 34.3 months, 2-, and 3-year...
The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma.
16/06/2021
/
Publications
/
Toxicity
This study reported the outcomes of 20 patients with primary (N=18), metastatic (N=3), or recurrent (N=2) inoperable pelvic (70%) or craniofacial (30%)...
Proton Therapy for Primary Bone Malignancy of the Pelvic and Lumbar Region - Data From the Prospective Registries ProReg and KiProReg.
16/02/2022
/
Publications
/
Toxicity
Eighty-one patients with primary bone malignancy, including Ewing’s sarcoma (58%), chondrosarcoma (7.4%), chordoma (24.7%), osteosarcoma (7.4%), and...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.